BRAF p.K601E is an activating mutation occurred in 0.15% of all NSCLC patients and showed low sensitivity to BRAF-targeted therapy in clinical studies 25-29, which could mediate crizotinib resistance in treatment. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.